@article{ed03671cab514f058aa1dc81590fdbe7,
title = "Comparison of 30-Day Serious Adverse Clinical Events for Elderly Patients Presenting to the Emergency Department With Near-Syncope Versus Syncope",
abstract = "Study objective: Controversy remains in regard to the risk of adverse events for patients presenting with syncope compared with near-syncope. The purpose of our study is to describe the difference in outcomes between these groups in a large multicenter cohort of older emergency department (ED) patients. Methods: From April 28, 2013, to September 21, 2016, we conducted a prospective, observational study across 11 EDs in adults (≥60 years) with syncope or near-syncope. A standardized data extraction tool was used to collect information during their index visit and at 30-day follow-up. Our primary outcome was the incidence of 30-day death or serious clinical events. Data were analyzed with descriptive statistics and multivariate logistic regression analysis adjusting for relevant demographic or historical variables. Results: A total of 3,581 patients (mean age 72.8 years; 51.6% men) were enrolled in the study. There were 1,380 patients (39%) presenting with near-syncope and 2,201 (61%) presenting with syncope. Baseline characteristics revealed a greater incidence of congestive heart failure, coronary artery disease, previous arrhythmia, nonwhite race, and presenting dyspnea in the near-syncope compared with syncope cohort. There were no differences in the primary outcome between the groups (near-syncope 18.7% versus syncope 18.2%). A multivariate logistic regression analysis identified no difference in 30-day serious outcomes for patients with near-syncope (odds ratio 0.94; 95% confidence interval 0.78 to 1.14) compared with syncope. Conclusion: Near-syncope confers risk to patients similar to that of syncope for the composite outcome of 30-day death or serious clinical event.",
author = "Aveh Bastani and Erica Su and Adler, {David H.} and Christopher Baugh and Caterino, {Jeffrey M.} and Clark, {Carol L.} and Deborah Diercks and Hollander, {Judd E.} and Malveau, {Susan E.} and Nicks, {Bret A.} and Nishijima, {Daniel K.} and Shah, {Manish N.} and Stiffler, {Kirk A.} and Storrow, {Alan B.} and Wilber, {Scott T.} and Yagapen, {Annick N.} and Weiss, {Robert E.} and Sun, {Benjamin C.}",
note = "Funding Information: Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org ). Dr. Bastani reports receiving research funding from Radiometer and Portola and has been a consultant for Portola. Dr. Adler reports receiving funding from Roche . Dr. Caterino reports receiving funding from AstraZeneca . Dr. Clark reports receiving research funding from Radiometer, Ortho Clinical Trials, Janssen, Pfizer , National Institutes of Health (NIH), Portola , Biocryst , GlaxoSmithKlein, the Hospital Quality Foundation , and Abbott , and is a consultant for Portola, Janssen , and the Hospital Quality Foundation. Dr. Diercks is a consultant for Janssen and Roche, reports receiving institutional research support from Novartis , Ortho Scientific, and Roche, and is on the editorial board for Academic Emergency Medicine and Circulation. Dr. Hollander reports receiving research funding from Alere , Siemens , Roche, Portola, and Trinity. Dr. Nishijima reports receiving honorarium from Pfizer. Dr. Storrow is a consultant for Siemens and Quidel and is on the data and safety monitoring board for Trevena. Dr. Sun is a consultant for Medtronic. This work was supported by a grant from the National Heart, Lung, and Blood Institute (grant NIH R01 HL 111033 ). Funding Information: Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Bastani reports receiving research funding from Radiometer and Portola and has been a consultant for Portola. Dr. Adler reports receiving funding from Roche. Dr. Caterino reports receiving funding from AstraZeneca. Dr. Clark reports receiving research funding from Radiometer, Ortho Clinical Trials, Janssen, Pfizer, National Institutes of Health (NIH), Portola, Biocryst, GlaxoSmithKlein, the Hospital Quality Foundation, and Abbott, and is a consultant for Portola, Janssen, and the Hospital Quality Foundation. Dr. Diercks is a consultant for Janssen and Roche, reports receiving institutional research support from Novartis, Ortho Scientific, and Roche, and is on the editorial board for Academic Emergency Medicine and Circulation. Dr. Hollander reports receiving research funding from Alere, Siemens, Roche, Portola, and Trinity. Dr. Nishijima reports receiving honorarium from Pfizer. Dr. Storrow is a consultant for Siemens and Quidel and is on the data and safety monitoring board for Trevena. Dr. Sun is a consultant for Medtronic. This work was supported by a grant from the National Heart, Lung, and Blood Institute (grant NIH R01 HL 111033). Publisher Copyright: {\textcopyright} 2018 American College of Emergency Physicians",
year = "2019",
month = mar,
doi = "10.1016/j.annemergmed.2018.10.032",
language = "English (US)",
volume = "73",
pages = "274--280",
journal = "Journal of the American College of Emergency Physicians",
issn = "0196-0644",
publisher = "Mosby Inc.",
number = "3",
}